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In our earlier study, we had reported the case of a patient with rheumatoid arthritis (RA), who had 
anti-Jo-1 antibodies. This patient had received etanercept (ETN) therapy for RA, after which she had 
developed overt polymyositis (PM). Although various autoimmune phenomena, including lupus-like 
diseases, vasculitides, or psoriatic skin lesions, are associated with anti-tumor necrosis factor (TNF) 
therapy, the development of PM/dermatomyositis (DM) or antisynthetase syndrome following anti-TNF 
therapy is extremely rare. Here, we report a case of an RA patient with anti-PL-12 antibodies, who 
received ETN therapy and subsequently developed the antisynthetase syndrome. She recovered when 
ETN therapy was withdrawn and high-dose corticosteroid was administered. To date, there have been 
only 5 reported cases of RA patients with anti-Jo-1 antibodies who developed overt PM/DM following 
anti-TNF therapy and only 1 case of antisynthetase syndrome in an RA patient with anti-PL-7 antibodies. 
Our patients and the abovementioned reports strongly suggest that onset of overt PM/DM or 
antisynthetase syndrome in RA patients with anti-aminoacyl t-RNA synthetase antibodies is associated 
with anti-TNF therapy.  
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We had previously reported the case of a patient with rheumatoid arthritis (RA), who had been positive 
for anti-Jo-1 antibodies and had developed polymyositis (PM) following etanercept (ETN) therapy for RA 
[1]. Although various autoimmune phenomena, including lupus-like diseases, vasculitides, or psoriatic 
skin lesions, associated with anti-tumor necrosis factor (TNF) therapy have been reported [2], the 
development of PM/dermatomyositis (DM) following anti-TNF therapy is extremely rare. Only 5 such 
cases have been reported, including our previous report [1, 3-7], and only 1 report has shown the 
association of antisynthetase syndrome with anti-TNF therapy against RA [7]. Here, we report a case of 
an RA patient with anti-PL-12 antibodies (an anti-aminoacyl tRNA synthetase [ARS] antibody) who was 
successfully treated with ETN therapy for active RA; however, the patient subsequently developed overt 
antisynthetase syndrome. 
Case report 
A 63-year-old woman, who had been treated for nonspecific interstitial pneumonia (NSIP) with 
prednisolone (PSL) and cyclosporine for 3 years, was diagnosed with RA because she had morning 
stiffness, systemic joint swelling and tenderness, elevated levels of inflammatory markers such as 
C-reactive protein (CRP), and elevated erythrocyte sedimentation rate (ESR). Moreover, her serum was 
positive for rheumatoid factor (RF) and anti-citrullinated-cyclic-peptide (CCP) antibody. At the time of 
RA diagnosis, NSIP was not active, and she did not have any respiratory symptoms while she was 
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receiving a maintenance dose of PSL without concomitant administration of cyclosporine. Although 
tacrolimus (TAC) was chosen as the disease-modifying antirheumatic drug (DMARD), it was only 
minimally effective for the treatment of arthritis, despite adequate duration of treatment. The maintenance 
dose of PSL was 10 mg daily. ETN (25 mg, twice daily) was administered along with TAC and PSL for 
the adequate control of active arthritis. Consequently, the joint swelling and tenderness subsided, and the 
levels of the inflammatory markers decreased rapidly. However, systemic arthralgia recurred 2 months 
after the initiation of ETN therapy; this was accompanied by low-grade fever and erythema on the trunk. 
In addition, the chest roentgenogram revealed exacerbation of ground-glass opacities. Since adverse drug 
reactions were suspected, ETN therapy was discontinued, but the symptoms persisted. The patient was 
admitted for further examination and treatment.  
On admission, she was mildly febrile, and we observed a flare-up of systemic joint swelling and 
tenderness after ETN cessation. She experienced dyspnea on exertion, but the arterial oxygen saturation 
and the findings of the pulmonary function test were almost normal. Trunk erythema disappeared 
completely, and eruptions, including Gottron’s papule, heliotrope rash, or mechanic’s hand, were not 
detected. She had no muscular symptoms, and manual muscle tests yielded normal findings. Further, 
nerve conduction study and electromyography did not reveal any specific abnormal findings. Plain 
radiography of the joints of the hands and feet revealed periarticular osteoporosis, multiple bony erosions, 
and joint space narrowing, thereby indicating stage II RA of the Steinbrocker classification. Chest 
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roentgenography and computed tomography showed exacerbation of interstitial markings at the base of 
both the lungs (Figure 1). Laboratory examinations revealed that the CRP level was 6.9 mg/dL; ESR, 85 
mm/h; and IgG level, 2,538 mg/dL. The creatine kinase level was normal. The autoantibody profiles 
showed IgM-RF level of 284 IU/mL, anti-CCP antibodies of >100 U/mL, 1:320 fluorescent antinuclear 
antibodies with speckled and nucleolar patterns, and anti-Sjogren’s syndrome antigen A (anti-SS-A/Ro) 
antibodies of 84.8 U/mL. In addition, the analysis of her serum by the RNA-immunoprecipitation (IPP) 
method with HeLa cell extracts revealed that her serum was positive for anti-PL-12 antibody. On the 
basis of these findings, she was diagnosed with antisynthetase syndrome. Treatment with 1 mg/kg of PSL 
was highly successful: dyspnea subsided and radiography images showed rapid disappearance of 
interstitial markings (Figure. 3, 4). Presently, she is healthy and she is receiving a maintenance dose of 
PSL, and the disease has not recurred. Although TAC is only a DMARD used for the control of RA, 




Fig. 1 Chest X-ray and computed tomography scan on admission, showing reticulonodular shadows 
at the base of both the lungs. 
 
 
Fig. 2 Chest X-ray and computed tomography scan after treatment, showing improvement of interstitial 
markings. 
Discussion  
Antisynthetase syndrome is characterized by many clinical features, including mild to moderate 
grade fever; polyarthritis, usually without joint destruction; interstitial lung disease (ILD), especially 
NSIP; and characteristic skin eruptions called mechanic’s hand, with or without inflammatory myositis in 
patients with anti-ARS antibodies [8]. Anti-ARS antibodies recognize ARSs in many cells, including 
myocytes; 6 major anti-ARS antibodies, of which the antigens are histidyl-(Jo-1) [9], alanyl-(PL-12) [10], 
threonyl-(PL-7) [11], isoleucyl-(OJ) [12], glycyl-(EJ) [12], and asparaginyl-tRNA synthetase (KS) [13], 
have been reported to date. However, the precise pathophysiological roles of these antigens have not yet 
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been clarified.  
Only 5 cases of PM/DM associated with anti-TNF therapy for RA have been reported so far [1, 3-6]. 
Four of these 5 patients, including ours, had anti-Jo-1 antibody before the initiation of anti-TNF therapy, 
and PM/DM resolved after the cessation of anti-TNF therapy and the initiation of corticosteroid (CS) 
therapy. In addition, 3 of the 4 patients and our patient had ILD, which exacerbated after anti-TNF 
therapy and subsided after CS therapy (Table 1). Anti-TNF agents used in these reports included 
infliximab and ETN. New onsets or flare of ILDs following anti-TNF therapies have also been reported, 
most of which were RA cases [2]. Although the profiles of anti-ARS antibodies in these RA patients were 
unclear, it is possible that some of the patients had anti-ARS antibodies that may have been associated 
with exacerbation of ILD. In addition, a Japanese article recently showed a case of an RA patient with 
anti-PL-7 antibody: this patient had developed overt antisynthetase syndrome following treatment with 
ETN for RA, but his condition had improved after he discontinued ETN therapy and began treatment with 
1 mg/kg of PSL [7]. This report is very similar to our case in its clinical course. Although present case did 
not show myositis, patients with anti-Jo-1 antibody show myositis more frequently than those with 
anti-PL-12 antibody [8]. On the other hand, anti-PL-12 antibody is more associated with ILD than with 
myositis [14]. Although several common clinical features characterize the antisynthetase syndrome, there 
are also some differences among patients with different anti-ARS antibodies, which will be clarified in a 
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※1ND Not done or Not described  ※2 DMARDs disease modifying anti-rheumatic drugs  ※3 HCQ hydroxychloropuine  ※4 
MTX methotrexate  ※5 BUC bucillamine  ※6 TAC tacrolimus  ※7 FANA fluorescent antinuclear antibody  ※8 Spe. 
Speckled  ※9 Ho. Homogenous  ※10 Nuc. Nucleolar  ※11 ILD interstitial lung disease  ※12 NSIP non-specific interstitial 
pneumonia  ※13 UIP usual interstitial pneumonia  ※14 All treatment include withdrawal of anti-TNF therapy  ※15 PSL 
prednisolone  ※16 AZP azathiopurine  ※17 MP methylprednisolon 
RA patients with anti-ARS antibodies may have a risk for developing antisynthetase syndrome after 
undergoing anti-TNF therapies. Screening the profiles of anti-ARS antibodies in RA patients is not 
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recommended because RNA-IPP is currently not performed routinely, and the frequency of positivity of 
the anti-ARS antibodies among RA patients is unclear. However, if anti-TNF therapy is initiated for the 
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